Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pasithea Therapeutics Corp. on July 10, 2025. The Company, an emerging growth company incorporated in Delaware, is headquartered in Miami Beach, Florida. The report specifically addresses the scheduling of the 2025 Annual Meeting of Stockholders and the associated deadlines for shareholder proposals and director nominations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing regarding corporate governance and does not contain financial performance data.
Material Changes
The material change reported is the official setting of the date for the 2025 Annual Meeting of Stockholders to September 3, 2025. This date is more than 30 days after the anniversary of the 2024 annual meeting, necessitating this specific 8-K filing to establish deadlines for shareholder actions.
Guidance, Outlook, and Management Commentary
- Annual Meeting Date: September 3, 2025.
- Proxy Materials: Expected to be delivered on or about July 24, 2025.
- Shareholder Proposal Deadline: Proposals under Rule 14a-8 must be received in writing by July 21, 2025.
- Director Nomination Deadline: Notice for universal proxy solicitations (Rule 14a-19) must be provided by July 21, 2025.
- Submission Address: 1111 Lincoln Road, Suite 500, Miami Beach, FL 33139.
Investor Verification Checklist
- Verify the exact date of the 2025 Annual Meeting (September 3, 2025) against the Company's investor relations calendar.
- Confirm the July 21, 2025 deadline for submitting Rule 14a-8 proposals and Rule 14a-19 director nominations.
- Monitor the release of proxy materials expected around July 24, 2025, for detailed agenda items.
- Note that this filing contains no financial updates; refer to the most recent 10-Q or 10-K for financial status.